SCHEMBL8155606

SCHEMBL8155606

O=C(CN1CCC(C(=O)c2ccc(F)cc2)CC1)Nc1ccc(C2CCCCC2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.81
LMNA P02545 3/20 0.81
HTT P42858 1/20 0.81
ALDH1A1 P00352 5/20 0.74
NPC1 O15118 1/20 0.62
USP2 O75604 1/20 0.62
HPGD P15428 1/20 0.62
POLB P06746 2/20 0.60
KDM4E B2RXH2 1/20 0.57
THRB P10828 1/20 0.57
TDP1 Q9NUW8 3/20 0.57
MAPT P10636 1/20 0.57
MAPK1 P28482 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C19 P33261 1/20 0.57
KMT2A Q03164 4/20 0.55
MEN1 O00255 2/20 0.55
UBE2N P61088 1/20 0.55
TSHR P16473 1/20 0.53
ATM Q13315 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7738147 0.81 ALDH1A1 (0.81) LMNAHTTALDH1A1NPC1USP2
SCHEMBL17731134 0.79 DRD4 (0.67) SMN1; SMN2LMNAHTTALDH1A1NPC1
SCHEMBL7738167 0.77 ALDH1A1 (1.00) SMN1; SMN2LMNAALDH1A1NPC1USP2
SCHEMBL7735984 0.76 ALDH1A1 (0.67) SMN1; SMN2ALDH1A1NPC1USP2HPGD
SCHEMBL8958804 0.76 SMN1; SMN2 (0.72) SMN1; SMN2LMNAHTTALDH1A1POLB
SCHEMBL22777878 0.75 ALDH1A1 (0.60) SMN1; SMN2LMNAHTTALDH1A1NPC1
SCHEMBL26154118 0.75 HDAC8 (0.76) SMN1; SMN2HTTNPC1MAPK1
SCHEMBL3454062 0.75 ALDH1A1 (0.73) SMN1; SMN2LMNAHTTALDH1A1KDM4E
SCHEMBL7476441 0.75 LMNA (0.64) SMN1; SMN2LMNAHTTALDH1A1KDM4E
SCHEMBL3379373 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6048900-A FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA BAYER CORPORATION (US) 2000-04-11 US disclosed